⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880019 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL8880391 | 0.79 | — | — | |
| SCHEMBL8879507 | 0.69 | MEN1 (0.35) | — | |
| SCHEMBL8879370 | 0.69 | TDP2 (0.32) | — | |
| SCHEMBL9007416 | 0.68 | HDAC8 (0.33) | — | |
| SCHEMBL8880983 | 0.68 | PSMB8 (0.31) | — | |
| SCHEMBL8880832 | 0.66 | — | — | |
| SCHEMBL8879933 | 0.65 | — | — | |
| SCHEMBL9007306 | 0.60 | — | — | |
| SCHEMBL8880389 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5607929-A | Antiviral dibenzothiazepinone derivatives | GLAXO WELLCOME INC. (US) | 1997-03-04 | — | — | US | claimed |
| EP-0583288-A1 | ANTIVIZAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | claimed |
| WO-1992019277-A1 | ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | claimed |
| US-5607929-A | Antiviral dibenzothiazepinone derivatives | GLAXO WELLCOME INC. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0583288-A1 | ANTIVIZAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992019277-A1 | ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |